Skip to content
DataLookout
Menu

NCT05120284

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 18 versions: 14 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 11 words Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Jul 1, 2026 to Aug 31, 2026
    • Enrollment target: estimated 40 to confirmed 37
    • Publications: details revised at 40 of 42 entries
  2. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v16
  3. Notable Primary completion date: Jun 2025 to Jul 1, 2026
    • Study completion date: Jun 2025 to Aug 31, 2026
    v14
  4. Minor Study sites: 3 to 2v13
  5. Minor Collaborators shortened, about 5 wordsv12
Show 8 earlier versionsHide 8 earlier versions
  1. Minor Site details revised at 1 of 3 sitesv11
  2. Minor Site details revised at 1 of 3 sitesv10
  3. Notable Eligibility criteria expanded, about 21 words
    • Primary endpoint revised
    • Study sites revised (3)
    v9
  4. Minor Site details revised at 1 of 3 sitesv7
  5. Notable Eligibility criteria expanded, about 27 words
    • Study sites: 1 to 3
    v5
  6. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2022 to Jul 1, 2022
    • Site details revised
    v4
  7. Notable Start date: Mar 2022 to Jun 2022v3
  8. Minor Study site revisedv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Level of phosphorylated PDC protein expressed in surgical tissue
Timeframe: Within 4 weeks post surgery

Arms and interventions

Pre-Surgical Dichloroacetate (DCA)Active comparator

Study medication begins in subjects randomized to preoperative DCA. All subjects will be given the 12.5 mg/kg/12 hour DCA for pre-surgical dosing. Post-surgery the GSTZ1 haplotype will be utilized to dose all patients.

No Pre-Surgical Dichloroacetate (DCA)Active comparator

Subject randomized to start DCA after surgery will do so 12-24 hours postoperatively, depending on their ability to safely receive medication.

Drugs: Dichloroacetate (DCA)

Genetic: Genotype

Sites

2 sites in 1 country